Abstract:Background: In the present study, we aimed to investigate the expression and prognostic value of co-stimulatory molecules, programmed death ligand-1 (PD-L1) and PD-L2, in ovarian cancer (OC). Methods: Immunohistochemical (IHC) staining was used to assess the expressions of PD-L1 and PD-L2 in 77 cases of OC, and 10 cases of benign ovarian cyst were employed as negative controls. Moreover, chi(2) test was used to analyze the correlation between the PD-L1/PD-L2 expression and clinicopathological parameters. Kaplan-Meier method was used to compare the effects of PD-L1/PD-L2 expression level on the overall survival (OS) of OC patients. Results: PD-L1 and PD-L2 were mainly expressed on membrane and in cytoplasm of OC cells. The high-expression rate of PD-L1 and PD-L2 in OC tissues was 44.16% (34/77) and 22.08% (17/77), respectively. The expression of PD-L1 in OC cells was significantly correlated with FIGO stage (P= 0.026), while its expression was not significantly correlated with other clinicopathological parameters. There was no significant correlation between PD-L2 and any clinicopathological parameters. Kaplan-Meier survival analysis showed that the OS of high PD-L1 expression group was significantly shorter compared with the low PD-L1 expression group (HR = 2.689, 95% CI: 1.400-5.163). Patients with high PD-L2 expression also exhibited significantly shorter OS (HR = 2.204, 95% CI: 1.037-4.682). Multivariable analysis displayed that high expression of PD-L1 (HR = 2.275, 95% CI: 1.120-4.169), high expression of PD-L2 (HR = 2.314, 95% CI: 1.136-4.714) and FIGO stage (HR = 11.229, 95% CI: 1.373-91.865) were independent prognostic factors of OC. When negative expressions of both PD-L1 and PD-L2 were used as a combined prognostic factor, the OS was significantly prolonged (HR = 3.396, 95% CI: 1.858-6.029). According to our previous studies, patients with negative PD-L1 expression and high T-bet(+) TIL infiltration have higher OS than other patients. Patients with positive PD-L1 expression and low T-bet(+) TIL infiltration exhibit the shortest OS. Collectively, our findings provided the basis for PD-1/PD-L1 or PD-1/PD-L2 blockade therapy for OC patients. Conclusions: Co-stimulatory molecules, PD-L1 and PD-L2, were highly expressed in OC tissues, and their expression levels were correlated with FIGO stage, age and prognosis. These results suggested that PDL1 and PD-L2 were involved in the occurrence and development of malignant OC, indicating their potential value in clinical diagnosis and prognosis of OC.

Increased Expression Of Pdgf-Bb Predicts Metastasis And Poor Prognosis In Ovarian Cancer Patients

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

Platelet-derived growth factor-D promotes ovarian cancer invasion by regulating matrix metalloproteinases 2 and 9.

Characterization of PD-L1 Expression and Its Prognostic Value in Patients with Ovarian Cancer

Identification of Molecular Markers Associated With Ovarian Cancer Prognosis Using Bioinformatics Analysis

Prognostic Value Of Pdcd-1 And Ctla-4 In Ovarian Cancer Patients

Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis

Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma

Identification of potential biomarkers in ovarian carcinoma and an evaluation of their prognostic value

Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer

Platelet-derived Growth Factor-D Expression Mediates the Effect of Differentiated Degree on Prognosis in Epithelial Ovarian Cancer.

Discordance of PD-L1 Expression in Primary and Metastatic Ovarian High-Grade Serous Carcinoma and Its Correlation with CD8 + Tumor-Infiltrating Lymphocytes and Patient Prognosis

Prognostic Implications of PPL Expression in Ovarian Cancer

A VEGF-dependent Gene Signature Enriched in Mesenchymal Ovarian Cancer Predicts Patient Prognosis

The Expression of VEGF and Dll4/Notch Pathway Molecules in Ovarian Cancer

Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis

Over-expression of CXCL2 is associated with poor prognosis in patients with ovarian cancer

Gene expression profiling analysis of ovarian cancer.

Prognostic Significance of Differential Expression of Angiogenic Genes in Women with High-Grade Serous Ovarian Carcinoma

Expression and Prognostic Value of PD-L1 and PD-L2 in Ovarian Cancer